{
  "docId": "019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "docSlug": "be407bbae8f9e005c3f7268aea2b4f13",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 34 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 34,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes a progress bar at the bottom indicating 'Intro' section.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2fc9-715d-b6e1-faa3fd3ed1eb/4",
  "deckHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb",
  "deckJsonHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb.json",
  "deckAnchorHref": "/decks/019de075-2fc9-715d-b6e1-faa3fd3ed1eb#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.08,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "1. ALS - Amyotrophic Lateral Sclerosis, Johns Hopkins Medicine\n2. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040, Nature Communications, 2016\n3. Management estimate",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45a7211b-1456-4901-9ca0-de2e9a74ae1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.65,
        "y": 0.6
      },
      "kind": "metric",
      "text": "~24% Growth in Patients by 2040 in the US and EU",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11a5293e-f96b-408d-917f-39d6268333fe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.35,
        "y": 0.38
      },
      "kind": "metric",
      "text": "+5,000 New cases of ALS each year (US)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "959d5a28-cb93-460b-9b79-553e8675dddb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.65,
        "y": 0.38
      },
      "kind": "metric",
      "text": ">80,000 ALS Patients in NeuroSense's planned target market",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "962134aa-b35e-48ae-9fea-a3d0c97e980e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.35,
        "y": 0.6
      },
      "kind": "metric",
      "text": "~$3B Annual Market Opportunity",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e39c0382-9dea-4582-8584-c8a0c1f87c57",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.55,
        "x": 0.35,
        "y": 0.18
      },
      "kind": "title",
      "text": "Treatment options for ALS is a dire unmet need with only three FDA approved drugs available: Riluzole, Edaravone, & Relyvrio. All with a mild therapeutic effect",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "09b27c21-3ad8-4e31-9ee2-f70233062a17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.25,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "title",
      "text": "ALS is an incurable neurodegenerative disease, causing complete paralysis and ultimately death within 2-5 years from diagnosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03887741-c661-4a1c-bb38-d7a612db6744",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "63123e23-900b-43b2-9397-5e86bc1a03e4",
      "evidence": "The slide has an action title that highlights the issue with current ALS treatment options.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 4,
      "beatId": "d052347b-c66e-4f68-a07d-820ca641582f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The document identifies the problem of limited ALS treatment options.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 5,
      "from": 4,
      "beatId": "a6f6d67b-e3b5-4237-8f7f-2d28ca4abd76",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem by highlighting the limitations of current treatments.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "dc659062-6b4a-4152-86a1-bfaaa43636cd",
      "evidence": "The document highlights the limitations of current treatments and the need for effective therapies.",
      "position": 0,
      "objective": "What is the cost of not developing effective ALS treatments?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}